- ►annals.org [PDF] SJ Hadziyannis, H Sette Jr, TR Morgan, V … - Annals of internal medicine, 2004 - Am Coll Physicians Background: Treatment with pegylated interferon (peginter- feron) and ribavirin
for 48 weeks is more effective than conven- tional interferon and ribavirin in
patients with chronic hepatitis C. Objective: To assess the efficacy and ... Cited by 1173 - Related articles - All 8 versions
- ►hemophilia.ca [PDF] MW Fried, ML Shiffman, KR Reddy, C Smith, G … - New England Journal of Medicine, 2002 - content.nejm.org MICHAEL W. FRIED, MD, MITCHELL L. SHIFFMAN, MD, K. RAJENDER REDDY, MD, COLEMAN
SMITH, MD, GEORGE MARINOS, MD, FERNANDO L. GONÇALES, JR., MD, DIETER
HÄUSSINGER, MD, MOISES DIAGO, MD, GIAMPIERO CAROSI, MD, DANIEL DHUMEAUX, ... Cited by 3148 - Related articles - BL Direct - All 18 versions
- ►hemophilia.ca [PDF] MP Manns, JG McHutchison, SC Gordon, VK … - The Lancet, 2001 - Elsevier 1530 patients with chronic hepatitis C were assigned interferon alfa-2b (3 MU
subcutaneously three times per week) plus ribavirin 1000–1200 mg/day orally,
peginterferon alfa-2b 15 μg/kg each week plus 800 mg/day ribavirin, or ... Cited by 3135 - Related articles - BL Direct - All 16 versions
- ►alkamal-lab.com [PDF] P Selection - Ann Intern Med, 2004 - Am Coll Physicians Stephanos J. Hadziyannis, MD; Hoel Sette Jr., MD; Timothy R. Morgan, MD; Vijayan
Balan, MD; Moises Diago, MD; Patrick Marcellin, MD; Giuliano Ramadori, MD; Henry
Bodenheimer Jr., MD; David Bernstein, MD; Mario Rizzetto, MD; Stefan ... Related articles - All 4 versions
G Davis, JB Wong, JG McHutchison, MP Manns, … - Hepatology, 2003 - infeksiyon.org Interferon-based regimens for the treatment of chronic hepatitis C have become
increasingly effective and are able to eradicate virus in more than one half of
cases. Early identification of patients who will not respond is desirable ... Cited by 564 - Related articles - View as HTML - All 9 versions
JG McHutchison, M Manns, K Patel, T Poynard … - Gastroenterology, 2002 - spcorp.com.cn JOHN G. MCHUTCHISON,* MICHAEL MANNS,‡ KEYUR PATEL,* THIERRY POYNARD,§ KAREN
L. LINDSAY, CHRISTIAN TREPO,¶ JULES DIENSTAG,# WILLIAM M. LEE,** CARMEN
MAK,‡‡ JEAN–JACQUES GARAUD,‡‡ and JANICE K. ALBRECHT,‡‡ FOR ... Cited by 518 - Related articles - BL Direct - All 9 versions
- ►tokb.ru [PDF] A Mangia, R Santoro, N Minerva, GL Ricci, V … - New England Journal of Medicine, 2005 - content.nejm.org From the Gastroenterology Unit, IRCCS Casa Sollievo della Sofferenza Hospital,
San Giovanni Rotondo (AM, RS, F. Spiri- to, AA); the Department of Internal Med-
icine, Hospital Canosa, Canosa (NM); the Department of Internal Medicine, ... Cited by 377 - Related articles - All 10 versions
DB Strader, T Wright, DL Thomas, LB Seeff… - Hepatology, 2004 - texasliver.com These recommendations provide a data-supported approach. They are based on the
following: (1) a formal review and analysis of the recently-published world
literature on the topic [Medline search]; (2) the American College of ... Cited by 1062 - Related articles - View as HTML - All 11 versions
- ►ucsf.edu [PDF] ML Shiffman, AM Di Bisceglie, KL Lindsay, … - Gastroenterology, 2004 - Elsevier The most effective therapy currently available for treatment of chronic
hepatitis C virus (HCV) is the combination of peginterferon and ribavirin. This
study evaluated the effectiveness of this treatment in patients who were ... Cited by 335 - Related articles - BL Direct - All 8 versions
M von Wagner, M Huber, T Berg, H Hinrichsen … - Gastroenterology, 2005 - Elsevier Background & Aims: Standard therapy of patients with chronic hepatitis C virus
(HCV) infected with HCV genotype-2 or -3 is the combination of pegylated
interferon-α and ribavirin for 24 weeks. Whether shorter treatment ... Cited by 256 - Related articles - All 14 versions
